“Historically, patients with HER2-positive metastatic colorectal cancer who have progressed following frontline therapy have had poor outcomes,” said John Strickler, M.D. and lead investigator of the MOUNTAINEER trial. “The FDA approval of a chemotherapy-free combination regimen that specifically targets HER2 is great news for these patients.”
Takeda has announced U.S. Food and Drug Administration (FDA) approval of FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
In the case of Dr. Paul O'Rourke – a 39-year-old, stage I rectal cancer survivor, and physician at Johns Hopkins – robotic-assisted surgery (RAS) was the surgical option he was fortunate he had.
Lillian Abreu was thirty years old and five months pregnant when she found out she had stage I colon cancer. Thankfully, she was able to immediately undergo a right hemicolectomy without further complication to her or her baby.
Taiho Oncology and Taiho Pharmaceutical have announced U.S. Food and Drug Administration (FDA) approval of Lonsurf alone or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have undergone two prior regimens of treatment.
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
People with RAS-mutated metastatic colorectal cancer (mCRC) have seen little progress in first-line treatment options over the past two decades, but that could soon change for thousands of new patients, according to a press release from Cardiff Oncology.
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.